All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10440120" target="_blank" >RIV/00669806:_____/22:10440120 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/22:00076110 RIV/00098892:_____/22:10157317 RIV/61989592:15110/22:73614772 RIV/00179906:_____/22:10440120 RIV/61988987:17110/22:A2302FJP

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=tKp6cWS8Ds" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=tKp6cWS8Ds</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1182/bloodadvances.2020003876" target="_blank" >10.1182/bloodadvances.2020003876</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

  • Original language description

    Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression-free survival (PFS) and overall survival. Genomic mutations occurring in the remaining clonal aberrant plasma cells (A-PCs) are linked to the development of drug resistance and disease relapse. Thus, personalized treatment based on the genomic profile of MRD could be highly beneficial and ultimately increase patients&apos; survival. However, although large-scale sequencing studies have characterized the genome of many malignancies, including MM, the genomic mutations present in MM MRD exist at the beginning of investigation. Here, we set up an exome sequencing analysis to identify genomic mutations characteristic for MM MRD and explore if they could mediate drug response, resistance, or disease progression.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood Advances

  • ISSN

    2473-9529

  • e-ISSN

    2473-9537

  • Volume of the periodical

    6

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    5

  • Pages from-to

    368-372

  • UT code for WoS article

    000753857400002

  • EID of the result in the Scopus database

    2-s2.0-85123507705